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Running title: Does “Does the term “Ultra-radical“ predict morbidity in AOC?  
 
ABSTRACT 
Objective: To determine which descriptors of cytoreductive surgical extent in advanced 
ovarian cancer(AOC) best predict post-operative morbidity.  
Design: Retrospective notes review. 
Setting: A gynaecological cancer centre in the United Kingdom. 
Population: 608 women operated on for AOC in 114 months at a tertiary cancer centre 
between 16/8/07-16/2/17.  
Methods: Outcome data were analysed by six approaches to classify extent of surgery. 
Standard/ultra-radical surgery; standard/radical/supra-radical surgery; presence/absence of 
gastrointestinal resections; low/intermediate/high surgical complexity score(SCS); presence 
of bowel anastomoses and/or diaphragmatic surgery; and presence/absence of multiple bowel 
resections. 
Main Outcome Measures: Major (grade 3-5) post-operative morbidity and mortality 
Results: 43(7.1%) patients experienced major complications. Grade 5 complications 
occurred in 6 patients(1.0%). Patients who underwent multiple bowel resections had a 
relative risk(RR) of 7.73(95%CI 3.92-15.26), high SCS RR of 6.12(95%CI 3.25-11.52); 
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diaphragmatic surgery and gastrointestinal anastomosis RR 5.57(95%CI 2.65 – 11.72); “any 
gastrointestinal resection” RR 4.69(95%CI 2.66-8.24); ultra-radical surgery RR 4.65(95%CI 
2.26-8.79); supra-radical surgery RR 4.20(95%CI 2.35-7.51) of grade 3-5 morbidity as 
compared to those undergoing standard surgery as defined by NICE. No significant 
difference was seen in the rate of major morbidity between standard (6/59,10.2%) and ultra-
radical (9/81,11.1%) surgery within the cohort who had intermediate complex surgery 
(p>0.05).  
Conclusions: Numbers of procedures performed significantly correlates with major 
morbidity. The number of procedures performed better predicted major post-operative 
morbidity than the performance of certain “high risk” procedures. We recommend the SCS to 
define a higher-risk operation. NICE should re-evaluate the use of the term “ultra-radical” 
surgery. 
 
Funding: None 
 
Keywords: Ovarian cancer; surgery; morbidity; ultra-radical, NICE 
 
Tweetable abstract 
Multiple bowel resection is the best predictor of morbidity and more predictive than ‘ultra-radical 
surgery’ 
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INTRODUCTION 
The management of advanced ovarian cancer (AOC) consists of cytoreductive surgery in 
conjunction with platinum-based chemotherapy. Traditionally cytoreductive surgery has 
focused on pelvic, nodal and omental surgery yet increasingly procedures to treat abdomen 
wide locations of disease have been utilised such as diaphragmatic, splenic, liver and 
gastrointestinal resections. In spite of studies comparing European and American patients, 
who received more extensive surgery than UK patients with correspondingly elevated 
cytoreduction rates (1, 2), it was only in 2013 that the National Institute for Health and Care 
Excellence (NICE) implemented guidelines for the widespread use of such procedures (3), an 
approach which was further endorsed by the Chief Medical Officer in their annual report the 
following year (4). 
In their 2013 guidance (3), NICE expressed caution regarding advanced cytoreductive 
procedures, so called “ultra-radical” surgery, due to the elevated major morbidity rates of 12-
19% seen in patients receiving such surgery compared to 4-5% in those receiving “standard” 
treatment. The NICE guidance was, therefore, defining a group with a perceived elevated risk 
of morbidity, by the types of procedures performed, not the number of procedures performed. 
This approach contrasts with previous attempts to describe the extent of surgery, such as that 
suggested by Alletti (5), where the extent of surgical complexity is determined by the total 
number of surgical procedures performed rather than the intrinsic perceived risk of individual 
procedures themselves.  
Predicting which patients will have a non-standard recovery following cytoreductive surgery 
for advanced ovarian cancer remains elusive. Tools such as P-POSSUM (6) or the American 
College of Surgeons National Surgical Quality Improvement Programme (NSQIP) (7) have  
limited value in accurately predicting the risk of major complications following multi-
visceral resection in ovarian cancer patients (8). A method of predicting postoperative 
morbidity ideally prior to, but equally at the end of, surgery would be useful for the patient, 
the surgical team and those planning resource allocation. Such data would also enable 
national and international comparison.   
The aim of this study was to compare the efficacy of various classifications used to describe 
cytoreductive surgery on their ability to predict the development of post-operative morbidity. 
In doing so we sought to determine if morbidity in cytoreductive surgery could be explained 
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by the cumulative trauma from the number of procedures performed rather than an intrinsic 
risk profile of certain “ultra-radical” procedures themselves. 
 
METHODS 
Patients  
We undertook a retrospective review of all patients diagnosed with stage 3 or 4 AOC 
between 16th August 2007 and 16th February 2017. All patients were managed by 
subspecialty trained gynaecological oncologists at the Pan-Birmingham Gynaecological 
Cancer Centre (PBGCC). Cases were identified from the prospectively recorded 
gynaecological oncology multidisciplinary team (MDT) database after approval was obtained 
from the hospital research and development department. 
Patients were included in this study if they were referred from a local primary care provider 
to the PBGCC, underwent a midline laparotomy and had a final histological diagnosis of 
stage 3 or 4 epithelial ovarian, tubal or peritoneal cancer (AOC).  Quaternary referrals from 
outside the region were excluded from this analysis. All patients were considered on an 
“intention to treat basis” to allow for complete denominator data to be available.  
At PBGCC, the initial assessment of women with suspected AOC consists of clinical 
examination, transvaginal ultrasound scan, serum CA125 assay and CT scan of the thorax, 
abdomen and pelvis. All imaging is reviewed by specialist gynaecological cancer 
radiologists.   Following discussion at the MDT meeting, women either undergo: primary 
debulking surgery (PDS) or receive 3-4 cycles carboplatin AUC 6 +/- paclitaxel 175mg/m2 
based neoadjuvant chemotherapy (NACT) with an intention to consider interval debulking 
surgery (IDS), or palliation.  
Typically, surgical procedures include pelvic clearance, omentectomy, and 
lymphadenectomy.  More extensive surgery was introduced in 2008. In appropriately selected 
patients, gastro-intestinal surgery or radical upper abdominal procedures are also undertaken 
if required. Extensive stripping of the para-aortic lymph nodes is not performed routinely but 
enlarged para-aortic lymph nodes are resected. Following surgery all histology receives 
central review by specialist histopathologists. 
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Post-operative morbidity is recorded at our institution using the Memorial Sloane-Kettering 
Cancer Centre complication grading system (9, 10) (Table S1). For this study, only major 
morbidity (grades 3, 4, and 5) was recorded with patients classified by the highest recorded 
complication.  Morbidity was both retrospectively obtained from patients’ notes and 
prospectively recorded following critical incident review of major morbidity during the 
weekly MDT discussion.  
The following data was recorded: age; BMI; organ of origin; histological subtype; grade; 
stage; approach to cytoredution (primary or interval debulking surgery); cytoreductive 
outcome (complete (R0), optimal <1cm (R1) and suboptimal (R2)); SCS; major morbidity 
(grade 3+). 
Data Analysis  
Two types of classification systems were evaluated: (i) scoring systems that assessed the 
types of surgery used to indicate more complex surgery and (ii) scoring systems that 
measured the numbers of procedures performed. Within this framework six methods of 
classification were examined (Table 1). 
The first approach identifies high-risk surgery by inclusion of certain procedures. Three 
styles of assessment were evaluated: (i) NICE classification of standard and ultra-radical 
surgery; (ii) Pomel classification into standard, radical and supra-radical surgery (11); and 
(iii), a novel assessment grouping patient by the presence or absence of gastrointestinal 
resections.  
For the purpose of this study, gastro-intestinal surgery contributions to cytoreduction was 
considered ultra-radical if it fulfilled the criteria stated by NICE i.e. multiple resections of the 
bowel (excluding localised colonic resection) (3). Patients that underwent gastrointestinal 
surgery that did not meet this definition were analysed in the standard surgery group. 
Localised colonic resection was taken to mean a rectosigmoid resection. 
The second approach examined the number of procedures performed, thereby defining higher 
risk surgery in terms of the cumulative surgical “load”. Three styles of classifications were 
evaluated : (a) a modified surgical complexity score (SCS), as advocated by Alletti (5), which 
categorised surgeries into low, intermediate and high complexity groups (Appendix S1); (b) 
by the presence of bowel anastomoses and/or diaphragmatic surgery; and (c) the presence or 
absence of multiple bowel resections. 
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The SCS was modified to include procedures outside of the SCS with groin dissection, 
nephrectomy and partial gastrectomy each giving an additional one point to the total score. 
With respect to diaphragmatic stripping and lymphadenectomy, points were registered only in 
the context of a systematic regional treatment. (Appendix S1) 
We calculated the relative risk of major morbidity detected by the respective criteria with 
reference to standard surgery as defined by NICE for each of these six descriptions (i, ii and 
iii and a, b and c) of surgical radicality. 
No core outcome sets were relevant for this study. Furthermore, no patient involvement was 
required, although the results are now used in guidance for women considering cytoreductive 
surgery for AOC. No funding was received for this study. 
Statistical Analysis 
Categorical variables were compared with the chi-squared test and parametric and non-
parametric continuous variables were compared with the ANOVA or Kruskal-Wallis test 
respectively. Survival data was calculated using the Kaplan-Meier method. All tests were 
two-sided and a p-value of less than 0.05 was regarded as being statistically significant. 
RESULTS 
Between 16th August 2007 and 16th February 2017, 858 patients received treatment for AOC 
at the PBGCC.  Of these, 610 (71%) underwent cytoreductive surgery with 248 (29%) 
receiving chemotherapy or palliation alone. Of the patients who underwent cytoreductive 
surgery, 209 (34%) underwent primary debulking surgery (PDS) with 399 (66%) undergoing 
interval debulking surgery (IDS). R0, R1 and R2 cytoreduction was achieved in 65%, 14% 
and 21% respectively. Two patients were excluded from the analysis due to inadequate 
morbidity data. Survival outcomes and other outcomes have been previously published (12-
15). 608 patients were therefore available for analysis. 
1.  Analysis based on NICE classification 
When classified by the NICE guidance, 453 (74.5%) patients underwent standard surgery and 
155 (25.5%) patients underwent ultra-radical surgery. Overall patient demographics are 
demonstrated in Table 2.  Patients’ age, body mass index and grade distribution was similar 
in both groups. IDS was performed no more frequently (69.9% versus 64.2%, p> 0.05) but 
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complete cytoreduction rates were significantly higher (87.7% versus 56.7%, p< 0.0001) in 
the ultra-radical group compared to the standard surgery group (Table 2). 
Six patients (1%) died (grade 5 morbidity) as a consequence of: bowel ischaemia following 
mesenteric thrombosis; pneumonia and acute respiratory distress syndrome (ARDS); 
pancreatitis leading to ARDS; pulmonary embolus; renal failure; and multi-organ failure due 
to intra-abdominal sepsis. Four of these patients received standard surgery and two ultra-
radical surgery with corresponding mortality rates of 0.9% and 1.2% respectively. It should 
however be noted that of the patients who underwent standard surgery, three of the four 
deaths occurred in sub-optimally cytoreduced patients. Major morbidity was most commonly 
due to: post-operative chest drain insertion (n=5); re-operation for bleeding/haematoma 
(n=5); anastomotic leaks (n=4); or pelvic collections (n=4) (Table 3).  
2.  Analysis based on Surgical Complexity Score 
When classified using the SCS, 400 patients underwent low complexity surgery, 140 patients 
underwent intermediate complexity surgery and 68 patients underwent high complexity 
surgery.  As the SCS increased, so too did the rate of grade 3+ post-operative complications 
(r=0.9). A similar trend was seen when analysing patients grouped by their SCS score with 
low, intermediate and high surgical complexity groups experiencing 3.0%, 10.7% and 23.5% 
major morbidity respectively (Figure S1). 
A subgroup analysis was performed examining the difference in major morbidity across the 
three SCS groups according to PDS or IDS. Major morbidity occurred in 7/136 (5.1%), 4/51 
(7.8%) and 5/22 (22.7%) of patients undergoing low, intermediate or high complexity surgery 
with PDS. In those receiving IDS the corresponding rates of major morbidity were: 5/264 
(1.9%), 11/87 (12.6%) and 11/41 (26.8%). No significant difference was seen between PDS 
and IDS (p>0.05).  
3. Analysis of relative risks with respect to different methods of classification.  
Six approaches (Table 1) were evaluated on their ability to be predictive of complications 
relative to standard surgery as defined by NICE (Table 4).  
The highest relative risks of major complications were seen in definitions assessing the 
number of procedures performed. Patients who underwent multiple bowel resections were 
nearly 8 times more likely to have major post-operative morbidity than patients who had 
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standard surgery according to the NICE classification (RR 7.73, 95% CI 3.92-15.26).  
Patients were approximately 6 times more likely to have a major complication relative to 
standard surgery as defined by NICE if they had a high SCS (RR 6.12 95% CI 3.25-11.52) or 
received both diaphragmatic surgery with a gastrointestinal anastomosis (RR 5.57 95%CI 
2.65 – 11.72). 
Definitions based upon the performance of specific procedures were less useful in identifying 
post-operative morbidity. Patients receiving ultra-radical surgery compared to standard 
surgery as defined by NICE were only four times more likely to experience major 
complications (RR 4.65, 95% CI 2.26-8.79). This relative risk was similar to supra-radical 
surgery as defined by Pomel (RR 4.20, 95% CI 2.35-7.51). However, such definitions were 
marginally inferior to that of the solitary criteria of “any gastrointestinal resection” (RR 4.69, 
95%CI 2.66-8.24). Additionally, patients undergoing ultra-radical surgery as defined by 
NICE experienced 58.1% of all major complications in the cohort whereas the definition of 
“any gastrointestinal resection” identified 72.1% of all major complications (Table 4). 
To further investigate the potential for the ultra-radical definition to underestimate major 
morbidity, a comparison was performed amongst all patients with a SCS of 4-7 (intermediate 
surgical complexity) with patients subdivided into those that received standard surgery and 
those that received ultra-radical surgery according to NICE. Patients undergoing surgery of 
intermediate complexity were used in this analysis because within this group there were 59 
(42.1%) patients undergoing NICE standard surgery and 81 (57.9%) patients undergoing 
NICE ultra-radical surgery.  Patients undergoing surgery of low complexity predominantly 
had NICE standard surgery and patients undergoing surgery of high complexity 
predominantly had NICE ultra-radical surgery, hence both these groups would have provided 
a meaningless comparison.  No significant differences were seen in the rate of major 
morbidity between standard (6/59, 10.2%) and ultra-radical (9/81, 11.1%) procedures within 
the cohort who had intermediate SCS scores (p>0.05). 
4. Survival data 
The median overall survival (OS) for all patients receiving surgery was 48.2 months (95%CI 
40.6-55.8). In patients that underwent PDS and achieved R0, the median OS had not been 
reached as of August 2017. The estimated mean OS however was 83.9 months (95% CI 75.2 
– 92.7).  In patients that underwent PDS and achieved R1 or R2, the median OS was 56.3 
months (95% CI 25.8-86.8) and 15.0 months (95% CI9.1-20.8) respectively. In patients 
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undergoing IDS, the median OS was 57.9 months (95% CI 43.2-72.7) in R0, 33.4 months 
(95% CI 25.0-41.7) in R1 and 28.4 months (95% CI 21.6 – 35.2) in R2. In patients not 
receiving surgery, the median OS was 11.7 months (95% CI 8.3 – 15.0). 
DISCUSSION 
Main findings 
Our study demonstrates that the number of procedures performed significantly correlates with 
an increased risk of major morbidity. Additionally, we found that the number of procedures 
performed are a better predictor of major post-operative morbidity than the performance of 
certain “high risk” procedures alone. The NICE definition of ultra-radical surgery was a less 
useful predictor of major complications compared to the solitary criterion of ‘any 
gastrointestinal resection’.  
Strengths and Limitations 
The main strength of this study is the availability of total patient descriptors and the volume 
of cases arising from an early adopter of maximum effort cytoreduction in the UK.  As a 
retrospective review of practice, our results do however need to be interpreted with caution. 
Certain procedures, including liver resections and partial gastrectomies, were infrequently 
performed and therefore our results may be inaccurate in patients undergoing these 
procedures.  Furthermore, given the high rate of IDS observed in this study, our findings may 
be less generalizable to centres performing a greater proportion of PDS.  We appreciate the 
wide confidence intervals and recommend a suitably powered, prospective study to confirm 
our findings.  
Interpretation  
As the extent of surgery increases, so too does the risk of major morbidity. It is hardly 
surprising that patients treated with ‘ultra-radical’ surgery experience higher rates of major 
complications than patients managed with standard surgery (16-18). Although surgical 
complexity has long been associated with post-operative morbidity (19-21), our study is the 
first to demonstrate that standard and ‘ultra-radical’ surgery of similar surgical complexities 
have similar major complication rates suggesting that the actual number of procedures 
performed is a more important driver of post-operative morbidity than procedure types 
themselves.  
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Of the five studies originally describing their morbidity following the introduction of 
advanced surgical procedures, all can be considered studies of an ethos change towards multi-
visceral resection, and thus it is unsurprising that all demonstrated a mean number of 
advanced procedures per patient between 1.6 and 2.2 (2, 16-18, 22). Similar results were seen 
in single centre studies examining isolated organ resection in cytoreductive surgery. 
Magtigbays’ study of 112 patients undergoing splenectomy witnessed 61 additional 
urological/colorectal procedures (23). Tsoloakidids’ study of 89 patients undergoing 
diaphragmatic resection saw 32 additional advanced procedures utilised (24). Isolated pelvic 
disease is uncommon in AOC (25) and hence multiple advanced procedures may be required 
to achieve cytoreductive targets. 
Our findings indicate that the morbidity risk is higher after high complexity surgery, 
diaphragmatic surgery with a colorectal anastomosis and multiple bowel resections.  This 
supports the theory that the overall surgical ‘load’ is a significant driver of post-operative 
morbidity and is better predictor than certain specific procedures.  
‘Ultra-radical’ procedures have been utilized in isolation in other conditions with acceptable 
safety profiles (26-28) and previous reviews of advanced surgical procedures at the PBGCC 
only observed significantly increased morbidity in those patients who underwent multi-
visceral resections (12, 29). 
In Alleti’s paper, although surgical complexity was associated with major morbidity, 
subgroup analysis did not demonstrate a difference between various age and morbidity 
groups at similar surgical complexity levels (20). Similar findings were seen when the age-
adjusted Charleston co-morbidity index was used in primary (10) and interval (14) 
cytoreductive surgeries. Such surprising results may be due to insufficient power as all 
studies showed a non-significant increase in post-operative morbidity with increasing age and 
morbidity. Therefore, a meta-analysis would be strongly recommended. It is likely that other 
factors manipulate the baseline risk such as: serum albumin; performance status; age; and 
preoperative morbidities. In our study, despite the high operated patient rate, risk from 
intervention may be underestimated in the elderly or co-morbid. It is essential that large core 
outcome data sets are developed with pooling of data to better describe individual patients’ 
risks of post-operative morbidity. Such data would give an additional way of benchmarking 
centre performance in addition to general cohort descriptors (13) and survival data.  
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Attempts to describe the postoperative course for individual patients have proven difficult in 
the gynaecological oncological setting. Pre-operative predictors of morbidity such as P-
POSSUM (6) or the American College of Surgeons National Surgical Quality Improvement 
Programme (NSQIP) (7) both have limited value in accurately predicting the risk of major 
complications following multi-visceral resection in ovarian cancer patients (8). Although 
international guidance incorporates complications rates into the therapeutic pathways, 
predicting postoperative morbidity in cytoreductive surgery for individual patients remains 
elusive (30).   
 
The SCS is a marker of surgical ‘load’ both as a measure of numbers of procedures as well as 
a weighting of each of the constituent parts. Although we have modified the SCS to include 
groin lymphadenectomy, nephrectomy and gastrectomy, our weighting was arbitrarily set at 
1. There are also procedures worthy of inclusion such as resection around the porta hepatis, 
the lesser sac, and coeliac axis and further studies to define what weight the SCS should give 
to these procedures should be encouraged. Despite this limitation, our study shows 
postoperative morbidity positively correlating with Aletti’s SCS. Additionally, it 
demonstrates that the relative risk of major morbidity is higher with definitions that assess 
numbers of procedures rather that those that assess types of procedures. We suggest that 
assessing surgery load is more useful than looking at what surgery is to be performed. It 
could be argued that the numbers of procedures needed cannot be predicted pre-operatively 
but studies pertaining to pre-operative prediction of required surgery have often focused on 
resectibility rather than surgical complexity (31). We suggest that, if it is considered 
appropriate to proceed with surgery, a crude assessment of the surgical complexity required 
can be achieved using clinical examination, cross-sectional imaging and, in selective cases, 
diagnostic laparoscopy. This assessment would allow for more informed patient choice 
regarding whether to undergo surgery.  
 
 
In its next review of the guidance regarding ultra-radical surgery, we urge NICE to clarify the 
role of gastrointestinal surgery in both standard and ultra-radical settings. In its present state, 
NICE defines ‘standard’ surgery as ‘radical’ with constituent parts of ‘bilateral salpingo-
oophorectomy, total abdominal hysterectomy, omentectomy and lymphadenectomy’(3) with 
no mention of bowel surgery. Ultra-radical surgery however requires ‘multiple resections of 
the bowel (excluding localised colonic resection)’(3).  There therefore remains a grey area 
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between standard and ultra-radical surgery encompassing single gastrointestinal resections 
especially of the small bowel and the extent of resection that renders a colonic resection 
‘localised’.  
 
In our study, the NICE definition of ultra-radicality failed to predict morbidity when 
compared to ‘any gastro-intestinal resection’. We therefore need to use a more accurate 
classification of surgical radicality to better inform patients, surgeons and resource allocators 
in the management of AOC.  
CONCLUSION  
Defining cytoreductive surgery in AOC in a meaningful way remains elusive. Traditional 
terms such as standard, radical, supra-radical or ultra-radical reflect on the progression of 
gynaecological oncology surgery from limited pelvic surgery to abdomen-wide surgery that 
covers the disease distributions. Such terms are emotive, often poorly defined and do little to 
quantify risks for patients. The numbers of procedures performed appears to be a more 
significant predictor of morbidity. We suggest using the approach advocated by Aletti to 
define a higher-risk operation and suggest that it should be the basis of any future 
development by NICE regarding the acceptable extent of surgery 
 
ACKNOWLEDGEMENTS 
None 
DISCLOSURE OF INTERESTS 
Sean Kehoe has received fees for lecturing for Astra Zeneca and Roche. 
Janos Balega has received personal fees from Astra Zeneca and Roche. 
All other authors have no declarations. Completed disclosure of interest forms are available 
to view online as supporting information. 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
CONTRIBUTION OF AUTHORSHIP  
Study Concept: AP, KS, JB, SS, AE 
Data collection: AP, RP, AE 
Manuscript preparation: AP, SS, JB, SK, RP, JN, KS, AE 
ETHICS APPROVAL  
This study had been approved by the hospitals’ research and development department. 
According to the Medical Research Council Health Research Authority, ethical approval was 
not required for this study. 
FUNDING 
None 
TABLE/FIGURE CAPTION LIST 
Table 1: Six descriptions of surgical radicality 
Table 2: Overall cohort data as defined by NICE. 
Table 3: Major complications in Standard and Ultra-radical surgery as defined by NICE 
Table 4: Postoperative morbidity by different radicality definitions. 
 
ONLINE SUPPORTING MATERIAL 
Table S1: Memorial Sloane–Kettering Cancer Centre complication grading system. 
Figure S1: Major postoperative morbidity in patients undergoing low, intermediate and high 
complexity surgery. 
Appendix S1: Adjusted Aletti surgical complexity score (SCS) 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
REFERENCES 
1. Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit 
patients with less advanced ovarian cancer? Results from an international comparison within the 
SCOTROC-1 Trial. J Clin Oncol. 2005;23(34):8802-11. 
2. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved 
progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical 
paradigm. Gynecol Oncol. 2009;114(1):26-31. 
3. NICE. Ultra-radical (extensive) surgery for advanced ovarian cancer 2011. 
4. Department of health. Annual report of the chief medical officer, 2014 The health of the 
51%: Women 2014. 
5. Aletti GD, Podratz KC, Moriarty JP, Cliby WA, Long KH. Aggressive and complex surgery for 
advanced ovarian cancer: an economic analysis. Gynecol Oncol. 2009;112(1):16-21. 
6. Das N, Talaat AS, Naik R, Lopes AD, Godfrey KA, Hatem MH, et al. Risk adjusted surgical audit 
in gynaecological oncology: P-POSSUM does not predict outcome. Eur J Surg Oncol. 
2006;32(10):1135-8. 
7. Khuri SF, Daley J, Henderson W, Hur K, Demakis J, Aust JB, et al. The Department of Veterans 
Affairs' NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled 
program for the measurement and enhancement of the quality of surgical care. National VA Surgical 
Quality Improvement Program. Ann Surg. 1998;228(4):491-507. 
8. Szender JB, Frederick PJ, Eng KH, Akers SN, Lele SB, Odunsi K. Evaluation of the National 
Surgical Quality Improvement Program Universal Surgical Risk Calculator for a gynecologic oncology 
service. Int J Gynecol Cancer. 2015;25(3):512-20. 
9. Martin RC, 2nd, Jaques DP, Brennan MF, Karpeh M. Achieving RO resection for locally 
advanced gastric cancer: is it worth the risk of multiorgan resection? J Am Coll Surg. 
2002;194(5):568-77. 
10. Suidan RS, Leitao MM, Jr., Zivanovic O, Gardner GJ, Long Roche KC, Sonoda Y, et al. 
Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and 
survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. 
Gynecologic oncology. 2015;138(2):246-51. 
11. Pomel C, Dauplat J. [Management of malignant epithelial tumors of the ovary]. J Chir (Paris). 
2004;141(5):277-84. 
12. Phillips A, Pounds R, Balega J, Singh K. Histopathological correlation of splenic disease with 
radiological and surgical findings: should we incorporate into standard procedures for disseminated 
Mullerian adenocarcinoma? European journal of gynaecological oncology. 2016;37(5):678-84. 
13. Phillips A, Balega J, Nevin J, Singh K, Elattar A, Kehoe S, et al. Reporting 'Denominator' data is 
essential for benchmarking and quality standards in ovarian cancer. Gynecol Oncol. 2017;146(1):94-
100. 
14. Phillips A, Singh K, Pounds R, Sundar S, Kehoe S, Nevin J, et al. Predictive value of the age-
adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy 
usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for 
advanced epithelial ovarian cancer. Journal of obstetrics and gynaecology : the journal of the 
Institute of Obstetrics and Gynaecology. 2017:1-6. 
15. Phillips A. Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy 
confers a survival advantage in advanced ovarian cancer (in press). European Journal of Surgical 
Oncology. 2018. 
16. Kommoss S, Rochon J, Harter P, Heitz F, Grabowski JP, Ewald-Riegler N, et al. Prognostic 
impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann 
Surg Oncol. 2010;17(1):279-86. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
17. Rafii A, Stoeckle E, Jean-Laurent M, Ferron G, Morice P, Houvenaeghel G, et al. Multi-center 
evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for 
advanced ovarian cancer. PLoS One. 2012;7(7):e39415. 
18. Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J, et al. The incidence of major 
complications after the performance of extensive upper abdominal surgical procedures during 
primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol. 
2010;119(1):38-42. 
19. Iyer R, Gentry-Maharaj A, Nordin A, Burnell M, Liston R, Manchanda R, et al. Predictors of 
complications in gynaecological oncological surgery: a prospective multicentre study (UKGOSOC-UK 
gynaecological oncology surgical outcomes and complications). Br J Cancer. 2015;112(3):475-84. 
20. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-
term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American 
journal of obstetrics and gynecology. 2007;197(6):676 e1-7. 
21. Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, et al. A new frontier for 
quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term 
outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007;107(1):99-106. 
22. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, et al. The 
addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in 
patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103(3):1083-90. 
23. Magtibay PM, Adams PB, Silverman MB, Cha SS, Podratz KC. Splenectomy as part of 
cytoreductive surgery in ovarian cancer. Gynecol Oncol. 2006;102(2):369-74. 
24. Tsolakidis D, Amant F, Van Gorp T, Leunen K, Neven P, Vergote I. Diaphragmatic surgery 
during primary debulking in 89 patients with stage IIIB-IV epithelial ovarian cancer. Gynecol Oncol. 
2010;116(3):489-96. 
25. Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Werner L, et al. Intra-abdominal 
tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J 
Surg Oncol. 2009;99(7):424-7. 
26. Shea JA, Healey MJ, Berlin JA, Clarke JR, Malet PF, Staroscik RN, et al. Mortality and 
complications associated with laparoscopic cholecystectomy. A meta-analysis. Ann Surg. 
1996;224(5):609-20. 
27. Bagrodia N, Button AM, Spanheimer PM, Belding-Schmitt ME, Rosenstein LJ, Mezhir JJ. 
Morbidity and mortality following elective splenectomy for benign and malignant hematologic 
conditions: analysis of the American College of Surgeons National Surgical Quality Improvement 
Program data. JAMA Surg. 2014;149(10):1022-9. 
28. Vianelli N, Galli M, de Vivo A, Intermesoli T, Giannini B, Mazzucconi MG, et al. Efficacy and 
safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. 
Haematologica. 2005;90(1):72-7. 
29. Pounds R, Phillips A, Kehoe S, Nevin J, Sundar S, Elattar A, et al. Diaphragm disease in 
advanced ovarian cancer: Predictability of pre-operative imaging and safety of surgical intervention. 
Eur J Obstet Gynecol Reprod Biol. 2018;226:47-53. 
30. ESGO. Ovarian Cancer Surgery Guidelines. 2017. 
31. Axtell AE, Lee MH, Bristow RE, Dowdy SC, Cliby WA, Raman S, et al. Multi-institutional 
reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction 
in patients with advanced ovarian cancer. J Clin Oncol. 2007;25(4):384-9. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
